Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Participate in Upcoming Investor Conferences

GlobeNewswire November 12, 2024

Collegium Reports Record Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Collegium Appoints Vikram Karnani as Chief Executive Officer

GlobeNewswire November 7, 2024

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire October 24, 2024

Collegium Completes Acquisition of Ironshore Therapeutics

GlobeNewswire September 4, 2024

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 30, 2024

Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024

GlobeNewswire August 28, 2024

Collegium Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

GlobeNewswire July 29, 2024

Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire July 25, 2024

Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

GlobeNewswire June 13, 2024

Collegium to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Collegium Announces $35 Million Accelerated Share Repurchase Program

GlobeNewswire May 13, 2024

Collegium Reports First Quarter 2024 Financial Results

GlobeNewswire May 9, 2024

Collegium Announces CEO Transition

GlobeNewswire May 9, 2024

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER

GlobeNewswire April 29, 2024

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire April 25, 2024

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

GlobeNewswire April 11, 2024

Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire February 22, 2024